Polymorphism of gp41 glycoprotein might influence the progression to disease in HIV-1 infection

• Published in: AIDS (London) Vol. 27; no. 7; pp. 1189 - 1191
• Main Authors: Potard, Valérie, Ait-Arkoub, Zaïna, Agut, Henri
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 24.04.2013
• Subjects: Biological and medical sciences; Disease Progression; Female; Follow-Up Studies; Gene Expression Regulation; HIV Antibodies - genetics; HIV Antibodies - immunology; HIV Envelope Protein gp41 - genetics; HIV Envelope Protein gp41 - immunology; HIV Infections - genetics; HIV Infections - immunology; HIV-1 - genetics; HIV-1 - immunology; Human viral diseases; Humans; Immunodeficiencies; Immunodeficiencies. Immunoglobulinopathies; Immunoglobulin G - genetics; Immunopathology; Infectious diseases; Male; Medical sciences; Polymorphism, Single Nucleotide; RNA, Viral; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Viral Load; Immunopathology; Prognosis; HIV-1 virus; Glycoprotein; Retroviridae; AIDS; Immune deficiency; Lentivirus; Infection; Virus; Viral disease; Evolution; Human immunodeficiency virus; Polymorphism
• ISSN: 0269-9370; 1473-5571; 1473-5571
• DOI: 10.1097/QAD.0b013e32835f6b30

We analysed the impact of envelope glycoprotein gp41 polymorphism on the persistence of long-term nonprogressor (LTNP) status in 59 HIV-1-infected individuals over a period of time exceeding 6 years. The presence of a leucine at the codon 830, instead of the predominant isoleucine residue, was significantly associated with nonprogression, independently of the presence of two particular classes of antigp41 antibodies (antigp41 IgG2 and anti-SWSNKS peptide) previously reported as markers of LTNP status.